Sarcoma Oncology Research Center | Santa Monica, CA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will compare the efficacy and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory LMS who have received at least 1 prior line of systemic therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
360 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Patient Advocacy
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal